

REMARKS

Claim 15 has been amended so the language makes it clear that the transgenic mouse has the thrombotic response, not the mouse's genome.

The claims have been amended solely to make the language consistent with the intent of the claim. The claim scope has not been altered, and no new matter has been added. Claims 1, 3, 5, 10, 15, 21, 23, 26 and 28-30 are pending.

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned.

This paper is being filed timely as the issue fee is being paid concurrently herewith. No extensions of time are required. In the event any extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the amendment and remarks made herein is respectfully requested.

25 March 2005

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat  
Tracy M. Sioussat, Ph.D.  
Registration No. 50,609  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-374-7679  
Facsimile - 617-551-8820